Resveratrol Trial for Relief of Pain in Pseudoachondroplasia

Resveratrol Trial for Relief of Pain in Pseudoachondroplasia

The purpose of this study is to determine if self-administered oral resveratrol can dampen joint pain for individuals with pseudoachondroplasia compared to placebo. Another goal of this study is to evaluate side effects in this population.

Inclusion Criteria:

• The diagnosis of pseudoachondroplasia is based on clinical assessment either in person or by photographic review by skeletal dysplasia specialist (JTH),
• Healthy beyond pseudoachondroplasia associated complications,

Exclusion Criteria:

• Current use of resveratrol
• Current use of blood thinners, lovastatin, ketoconazole, itraconazole, fexofenadine and triazolam.
• Other non-pseudoachondroplasia related health conditions, e.g. cancers.
• Pregnancy or breastfeeding. Women must use adequate contraception during the study.
• Participation in another clinical study and/or using investigational agents.
• Use of Non-steroid anti-inflammatory (NSAIDs) or aspirin.
• Current use of Alfentanil, Cyclosporine, Dihydroergotamine, Dofetilide, Ergotamine, Fentanyl, Flibanserin, Oxycodone, Pimavanserin, Pimozide, Quinidine, Saquinavir, Sirolimus, Tacrolimus, Temsirolimus, Theophylline, Tizanidine, Thioridazine, Fosphenytoin, Phenytoin or Warfarin.
• Baseline level of pain of 2 or higher on 10 point scale.
• Platelet count below 50,000 per ul on baseline complete blood count (CBC).